Biodesix reported a 42% year-over-year jump in first-quarter 2026 revenue and raised full-year guidance after the company’s diagnostic testing business accelerated. Total Q1 revenue reached $25.6 million, topping consensus estimates, with diagnostic test revenue increasing 37% to $22.3 million. The company attributed growth to higher test volumes, up 29% year over year to 17,800, and improvements in payer coverage and revenue cycle management. Development services revenue more than doubled to $3.3 million. Biodesix increased its 2026 revenue outlook to $108 million–$114 million, with the midpoint implying 25% growth, highlighting demand strength for its molecular diagnostics and signaling confidence in continued execution.